SOLIGENIX INC | 1,068 Euro | -0,035 -3,17 % | |
| WKN: A1JTN9 ISIN: US8342232084 Ticker-Symbol: DOA1 | Berlin | 18.06.13 | 08:07 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 13.06. | SOLIGENIX, INC. - S-1/A, General form for registration of securities | 4 | SEC Filings | |
| 12.06. | SOLIGENIX, INC. - 10-K/A, Annual Report | 1 | SEC Filings | |
| 07.06. | Soligenix: The U.S. Government Is May Be Eyeing This Biotech | 4 | Seeking Alpha | |
| 03.06. | Soligenix gets fast track status for lead compound SGX942 | - | Proactive Investors | |
| 03.06. | FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer | 20 | PR Newswire | |
| PRINCETON, N.J., June 3, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program... Mehr lesen zu: FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer | ||||
| 23.05. | Soligenix' ThermoVax technology receives US patent | 2 | Pharma Bus Review | |
| 22.05. | Soligenix gets key Thermovax technology U.S. patent | 1 | Proactive Investors | |
| 22.05. | Soligenix Announces Issuance of US Patent for its ThermoVax' Technology | 13 | PR Newswire | |
| PRINCETON, N.J., May 22, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory... Mehr lesen zu: Soligenix Announces Issuance of US Patent for its ThermoVax' Technology | ||||
| 16.05. | Soligenix begins Phase 1 Crohn's disease study with SGX203 | - | Pharma Bus Review | |
| 15.05. | Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease | 21 | PR Newswire | |
| PRINCETON, N.J., May 15, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory... Mehr lesen zu: Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease | ||||
| 08.05. | SOLIGENIX, INC. - 8-K, Current Report | 1 | SEC Filings | |
| 06.05. | Soligenix's buy rating backed by Brean Capital amid "several positive developments" in Q1 | 1 | Proactive Investors | |
| 06.05. | Soligenix expands product pipeline with new biodefense collaboration for melioidosis | 2 | Proactive Investors | |
| 03.05. | Soligenix narrows Q1 loss as revenues increase, expenses decline; drug development continues | 1 | Proactive Investors | |
| 03.05. | Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments | 28 | PR Newswire | |
| PRINCETON, N.J., May 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory... Mehr lesen zu: Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments | ||||
| 01.05. | SOLIGENIX, INC. - 8-K, Current Report | 3 | SEC Filings | |
| 01.05. | Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration | 19 | PR Newswire | |
| PRINCETON, N.J. and GERMANTOWN, Md., May 1, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases... Mehr lesen zu: Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration | ||||
| 19.04. | Soligenix shares rise sharply in light of recent ricin threats | 5 | Proactive Investors | |
| 18.04. | Soligenix: Interesting Play In BioDefense Presenting At Today's Vaccine Expo | - | Seeking Alpha | |
| 16.04. | Soligenix to Present at World Vaccine Congress & Expo | 28 | PR Newswire | |
| PRINCETON, N.J., April 16, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products... Mehr lesen zu: Soligenix to Present at World Vaccine Congress & Expo | ||||
Seite: 1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| SCICLONE PHARMACEUTICALS | 3,597 | -0,64 % | SciClone to Present at Jefferies 2013 Global Healthcare Conference |
| STADA ARZNEIMITTEL | 33,75 | +0,33 % | DGAP-Stimmrechte: STADA Arzneimittel AG (deutsch) |
| BIOSANTE PHARMACEUTICALS | 0,949 | +3,94 % | BioSante Recommends Stockholders Vote For Proposed Merger With ANI Pharma |
| ACADIA PHARMACEUTICALS | 13,815 | -4,39 % | ACADIA PHARMACEUTICALS INC - 8-K, Current Report |
| SPECTRUM PHARMACEUTICALS | 6,134 | +1,27 % | Spectrum Pharmaceuticals Has Returned 26.6% Since SmarTrend Recommendation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von